A comparative study of the physicochemical properties of iron isomaltoside 1000 (Monofer®), a new intravenous iron preparation and its clinical implications

European Journal of Pharmaceutics and Biopharmaceutics

Volumn 78, Issue 3, 2011, Pages 480-491

  Jahn, Markus R ^a   Andreasen, Hans B ^b   Fütterer, Sören ^a   Nawroth, Thomas ^a   Schünemann, Volker ^c   Kolb, Ute ^a   Hofmeister, Wolfgang ^a   Muñoz, Manuel ^d   Bock, Klaus ^e   Meldal, Morten ^e   Langguth, Peter ^a  

^a JOHANNES GUTENBERG UNIVERSITY   (Germany)

^b Pharmacosmos AS   (Denmark)

^c Rheinland Pfälzische Technische Universität Kaiserslautern Landau   (Germany)

^d UNIVERSITY OF MÁLAGA   (Spain)

^e CARLSBERG LABORATORY   (Denmark)

Author keywords

Colloids; Free iron; Inorganic nanoparticles; Iron supplementation; Release rate; Stability

Indexed keywords

FERRIC CARBOXYMALTOSE; FERRIC GLUCONATE; FERRIC HYDROXIDE SUCROSE; FERUMOXYTOL; IRON; IRON DEXTRAN; IRON ISOMALTOSIDE 1000; MONOFER; UNCLASSIFIED DRUG;

ARTICLE; COMPARATIVE STUDY; CONTROLLED STUDY; DRUG FORMULATION; IMMUNOGENICITY; MOLECULAR WEIGHT; NONHUMAN; PARTICLE SIZE; PHARMACEUTICS; PHYSICAL CHEMISTRY; ZETA POTENTIAL;

DISACCHARIDES; DRUG COMPOUNDING; DRUG DELIVERY SYSTEMS; FERRIC COMPOUNDS; HUMANS; HYDROLYSIS; INFUSIONS, INTRAVENOUS; MOLECULAR STRUCTURE; MOLECULAR WEIGHT; PARTICLE SIZE; PHYSICOCHEMICAL PROCESSES; VITAMINS;

EID: 79960617268     PISSN: 09396411     EISSN: 18733441     Source Type: Journal    
DOI: 10.1016/j.ejpb.2011.03.016     Document Type: Article

References (47)

1. NICE-Guideline, Chronic Kidney Disease - National Clinical Guideline for Early Identification and Management in Adults in Primary and Secondary Care, National Institute for Health and Clinical Excellence, 2008.
2. W.H. Horl, I.C. Macdougall, J. Rossert, and R.M. Schaefer OPTA-therapy with iron and erythropoiesis-stimulating agents in chronic kidney disease Nephrology Dialysis Transplantation 22 2007
3. M. Muñoz, S. Gomez-Ramirez, and J.A. Garcia-Erce Intravenous iron in inflammatory bowel disease World Journal of Gastroenterology 15 2009 4666 4674
4. S.D. Anker, and C. Colet Ferric carboxymaltose in patients with heart failure and iron deficiency New England Journal of Medicine 361 2009 2436 2448
5. M. Muñoz, C. Breymann, J.A. García-Erce, S. Gómez-Ramírez, J. Comin, and E. Bisbe Efficacy and safety of intravenous iron therapy as an alternative/adjunct to allogeneic blood transfusion Vox Sanguinis 94 2008 172 183 (Pubitemid 351379653)
6. M. Auerbach, and H. Ballard Intravenous iron in oncology Journal of the National Comprehensive Cancer Network (JNCCN) 6 2008 585 592 (Pubitemid 352007766)
7. M. Muñoz, R. Leal-Noval, and J.A. García-Erce Intravenous iron in cardiac surgery Seminars in Hematology 2006 Elsevier S39 S42
8. C. Breymann, C. Richter, C. Huttner, R. Huch, and A. Huch Effectiveness of recombinant erythropoietin and iron sucrose vs. iron therapy only, in patients with postpartum anaemia and blunted erythropoiesis European Journal of Clinical Investigation 30 2000 154 161 (Pubitemid 30079574)
9. I.C. Macdougall Evolution of IV iron compounds over the last century Journal of Renal Care 35 2009 8 13
10. J.T. McCarthy, C.E. Regnier, C.L. Loebertmann, and E.J. Bergstralh Adverse events in chronic hemodialysis patients receiving intravenous iron dextran - a comparison of two products American Journal of Nephrology 20 2000 455 462 (Pubitemid 32037529)
11. R. Fletes, J.M. Lazarus, J. Gage, and G.M. Chertow Suspected iron dextran-related adverse drug events in hemodialysis patients American Journal of Kidney Diseases 37 2001 743 749 (Pubitemid 32268035)
12. G.M. Chertow, P.D. Mason, O. Vaage-Nilsen, and J. Ahlmen On the relative safety of parenteral iron formulations Nephrology Dialysis Transplantation 19 2004 1571 1575 (Pubitemid 38796422)
13. G.M. Chertow, P.D. Mason, O. Vaage-Nilsen, and J. Ahlme?n Update on adverse drug events associated with parenteral iron Nephrology Dialysis Transplantation 21 2006 378 382 (Pubitemid 43159991)
14. P. Geisser, M. Baer, and E. Schaub Structure/histotoxicity relationship of parenteral iron preparations Arzneimittel-Forschung 42 1992 1439 1452 (Pubitemid 23007362)
15. Division of Medical Imaging and Hematology Products and Office of Oncology Drug Products and Office of New Drugs, New Drug Application 22-054 for Injectafer (Ferric Carboxymaltose) for the Treatment of iron Deficiency Anemia in Patients with Heavy Uterine Bleeding or Postpartum Patients, FDA Advisory Committee Briefing Document, 2008, pp. 1-63.
16. W. Richter Hapten inhibition of passive antidextran dextran anaphylaxis in guinea pigs. Role of molecular size in anaphylactogenicity and precipitability of dextran fractions International Archives of Allergy and Immunology 41 1971 826 844
17. K.-G. Ljungström Invited commentary: pretreatment with dextran 1 makes dextran 40 therapy safer Journal of Vascular Surgery 43 2006 1070 1072
18. R.A. Zager, A.C. Johnson, S.Y. Hanson, and H. Wasse Parenteral iron formulations: a comparative toxicologic analysis and mechanisms of cell injury American Journal of Kidney Diseases 40 2002 90 103 (Pubitemid 34701216)
19. R.A. Zager, A.C. Johnson, and S.Y. Hanson Parenteral iron nephrotoxicity: potential mechanisms and consequences Kidney International 66 2004 144 156 (Pubitemid 38870090)
20. G. Glöckner Polymer Characterization by Liquid Chromatography 1987 Elsevier Science Ltd.
21. ICSH Revised recommendations for the measurements of the serum iron in human blood. Iron panel of the international committee for standardization in haematology British Journal Haematology 75 1990 615 616
22. H.Y.a.A.Z. Yee An autoanalyzer procedure for serum iron and total iron-binding capacity with use of ferrozine American Association of Clinical Chemistry 19 1971 950 953
23. P. Carter Spectrophotometric determination of serum iron at the submicrogram level with a new reagent (ferrozine) Analytical Biochemistry 40 1971 450 458
24. C.R. Gibbs Characterization and application of FerroZine iron reagent as a ferrous iron indicator Analytical Chemistry 48 1976 1197 1201
25. V.S. Balakrishnan, M. Rao, A.T. Kausz, L. Brenner, B.J.G. Pereira, T.B. Frigo, and J.M. Lewis Physicochemical properties of ferumoxytol, a new intravenous iron preparation European Journal of Clinical Investigation 39 2009 489
26. H.B. Andreasen, L. Christensen, Iron-dextran compound for the use as component in a therapeutical composition for prophylaxis or treatment of iron-deficiency, US Patent 6291,440, 2001.
27. M. te Booy, R.A. de Ruiter, and A.L.J. de Meere Evaluation of the physical stability of freeze-dried sucrose-containing formulations by differential scanning calorimetry Pharmaceutical Research 9 1992 109 114
28. 1H NMR spectroscopy Journal Carbohydrate Chemistry 13 1994 513 543
29. L. Gutiérrez, M. del Puerto Morales, and F. José Lázaro Magnetostructural study of iron sucrose Journal of Magnetism and Magnetic Materials 293 2005 69 74 (Pubitemid 40608911)
30. F. Funk, G.J. Long, D. Hautot, R. Büchi, I. Christl, and P.G. Weidler Physical and chemical characterization of therapeutic iron containing materials: a study of several superparamagnetic drug formulations with the β-FeOOH or ferrihydrite structure Hyperfine Interactions 136 2001 73 95
31. D.S. Kudasheva, J. Lai, A. Ulman, and M.K. Cowman Structure of carbohydrate-bound polynuclear iron oxyhydroxide nanoparticles in parenteral formulations Journal of Inorganic Biochemistry 98 2004 1757 1769 (Pubitemid 39456424)
32. M.R. Jahn, Y. Mrestani, P. Langguth, and R.H.H. Neubert CE characterization of potential toxic labile iron in colloidal parenteral iron formulations using off-capillary and on-capillary complexation with EDTA Electrophoresis 28 2007 2424 2429 (Pubitemid 47162937)
33. E.J. Coulson, and H. Stevens Some observations on the immunochemistry of dextrans The Journal of Immunology 86 1961 241
34. W. Richter Minimal molecular size of dextran required to elicit heterologous passive cutaneous anaphylaxis in guinea pigs International Archives of Allergy and Immunology 43 1972 252 268
35. W. Richter Built-in hapten inhibition of anaphylaxis by the low molecular weight subfractions of a B 512 dextran fraction of Mw 3400 International Archives of Allergy and Applied Immunology 45 1973 930
36. A.W. Richter Immune Complex Anaphylaxis Induced by Dextran and Its Elimination by Hapten Inhibition 1986 Springer-Verlag pp. 272-283
37. H. Hedin, W. Richter, K. Messmer, and H. Renck Incidence, pathomechanism and prevention of dextran-induced anaphylactoid/anaphylactic reactions in man Developments in Biological Standardization 48 1980 179
38. H. Renck, H.G. Ljungstrom, H. Hedin, and W. Richter Prevention of dextran induced anaphylactic reaction by hapten inhibition Acta Chirurgica Scandinavica 149 1983 355 360
39. K.G. Ljungström Safety of dextran in relation to other colloids - ten years experience with hapten inhibition Transfusion Medicine and Hemotherapy 20 1993 206 210
40. G.R. Aronoff Safety of intravenous iron in clinical practice: implications for anemia management protocols Journal of the American Society of Nephrology 15 Suppl. 2 2004 S99 106
41. S.B. Silverstein, and G.M. Rodgers Parenteral iron therapy options American Journal of Hematology 76 2004 74 78 (Pubitemid 38579543)
42. S. Fishbane, and E.A. Kowalski The comparative safety of intravenous iron dextran, iron saccharate, and sodium ferric gluconate Seminars in Dialysis 13 2000 381 384
43. B.G. Danielson Structure, chemistry, and pharmacokinetics of intravenous iron agents Journal of the American Society of Nephrology 15 Suppl. 2 2004 S93 98
44. M. Lu, K.R. Suh, H.-Z. Lee, M.H. Cohen, D. Rieves, and R. Pazdur FDA review of ferumoxytol (Feraheme) for the treatment of iron deficiency anemia in adults with chronic kidney disease American Journal of Hematology 85 2010 315 319
45. D.W. Coyne, and M. Auerbach Anemia management in chronic kidney disease: intravenous iron steps forward American Journal of Hematology 85 2010 311 312
46. D. Stainsby, H. Jones, D. Asher, C. Atterbury, A. Boncinelli, and L. Brant Serious hazards of transfusion: a decade of hemovigilance in the UK Transfusion Medicine Reviews 20 2006 273 282 (Pubitemid 44428107)
47. S. Santosh, P. Podarella, and B. Miller Anaphylaxis with elevated serum tryptase after administration of intravenous ferumoxytol NDT Plus 3 2010 341 342